GlassScriptPhysician profile
Shivas Gilotra
NPI 1972969913
$2,897.34
in general payments reported to CMS, 2019-2025
22 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,234 · 2022: $576 · 2023: $680 · 2024: $244 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $594.64 | 2021-2024 | Repatha, Otezla |
| Gilead Sciences, INC. | $504.40 | 2021-2023 | Descovy |
| Abbott Laboratories | $426.92 | 2021-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $351.38 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $207.67 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $104.24 | 2021 | |
| Irhythm Technologies, INC. | $101.08 | 2022 | |
| Organon LLC | $92.45 | 2021-2024 | Nexplanon |
| Hologic Sales and Service, LLC | $89.09 | 2023 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Pfizer INC. | $64.44 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.24 | 2021 | |
| Viiv Healthcare Company | $55.37 | 2022-2023 | Apretude |
| Abbvie INC. | $40.35 | 2021 | |
| Lilly USA, LLC | $35.97 | 2022-2023 | Mounjaro |
| Genentech USA, INC. | $35.61 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $29.13 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.71 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.48 | 2022 | |
| Eisai INC. | $20.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.69 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $14.10 | 2023 | Gardasil 9, Vaxneuvance |
| Sonex Health, INC. | $14.10 | 2023 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivas Gilotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.